Shire plc has entered into a definitive agreement to sell its Dermagraft assets to Organogenesis, Inc. at a loss of approximately $650 million. Shire is eligible to receive as much as $300 million in milestone payments if sales targets through 2018 are met. Dermagraft, a living skin substitute, is approved in the U.S. and Canada for the treatment of full-thickness diabetic foot ulcers.   Shire gained Dermagraft with the acquisition of Advanced BioHealing for $750 million in 2011. Just following ...